The versatile interplay between steatotic liver disease and liver cancer

A comprehensive review published in Nature Reviews Cancer examines how metabolic dysfunction-associated steatotic liver disease (MASLD) and alcoholic liver disease (ALD) drive the development of liver cancer through chronic liver injury and sustained inflammation. Rahbari and colleagues detail the distinct pathophysiological mechanisms by which each condition promotes hepatic carcinogenesis, highlighting that MASLD and ALD follow divergent molecular pathways despite sharing a common endpoint. The review surveys recent therapeutic advancements targeting these pathways and argues that more tailored, disease-specific strategies are needed to reduce cancer risk in affected patient populations. Given the rising global prevalence of metabolic liver disease, this synthesis offers timely guidance for clinicians and researchers working at the intersection of hepatology and oncology.